文献速递炎症性肠病

克罗恩病诊断后12个月内粪钙卫蛋白正常化与疾病进展风险降低相关

Normalization of Fecal Calprotectin Within 12 Months of Diagnosis Is Associated With Reduced Risk of Disease Progression in Patients With Crohn's Disease.
PubMed 文献 · Clin Gastroenterol Hepatol · 2020-08-13

该回顾性队列研究在英国的炎症性肠病中心纳入2005至2017年诊断的克罗恩病患者,分析诊断后12个月内粪钙卫蛋白(FC)正常化(<250 μg/g)与疾病进展的关系。结果显示43.5%患者FC正常化,其复合疾病进展风险显著降低(HR 0.36,95%CI 0.24-0.53,P<.001),各单独进展终点风险也降低。

要点

  • 诊断后12个月内FC正常化与复合疾病进展风险降低相关(HR 0.36)。
  • FC正常化患者蒙特利尔行为进展或新肛周病变风险HR 0.22。
  • FC正常化患者住院风险HR 0.33,手术风险HR 0.39。

核心结论

  • 克罗恩病诊断后12个月内粪钙卫蛋白正常化与疾病进展风险降低相关。

研究设计与样本

  • 回顾性队列研究,在英国一家三级炎症性肠病中心纳入2005至2017年诊断的克罗恩病 incident 病例。
  • 纳入诊断时FC≥250 μg/g、诊断后12个月内至少1次随访FC测量且随访>12个月的患者,共375例(来自1389例 incident 病例),中位随访5.3年(四分位距3.1-7.4年)。
  • 以诊断后12个月内最后一次FC测量判定正常化(截断值<250 μg/g)。
  • 主要终点为至首次疾病进展时间(复合终点:蒙特利尔疾病行为B1进展至B2/3、B2进展至B3或新发肛周病变;克罗恩病相关手术;或克罗恩病相关住院)。
  • 采用Cox比例风险回归分析确定与至首次疾病进展时间相关的独立因素。

主要发现

  • 43.5%的患者确认在诊断后12个月内FC正常化。
  • FC正常化患者复合疾病进展风险显著降低(HR 0.36;95%CI 0.24-0.53;P<.001)。
  • FC正常化患者蒙特利尔行为进展或新肛周病变风险HR 0.22(95%CI 0.11-0.45;P<.001)。
  • FC正常化患者住院风险HR 0.33(95%CI 0.21-0.53;P<.001)。
  • FC正常化患者手术风险HR 0.39(95%CI 0.19-0.78;P=.008)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: The level of fecal calprotectin (FC) correlates with endoscopic evidence of inflammation in Crohn's disease (CD). A treat-to-target algorithm for patients with CD, that incorporates FC, outperforms a treatment strategy based on symptoms alone in the induction of mucosal healing at 12 months. We investigated whether normalization of FC within 12 months of diagnosis of CD is associated with a reduction in disease progression. METHODS: We performed a retrospective cohort study at a tertiary IBD centre in the United Kingdom. We identified all incident cases of CD diagnosed from 2005 through 2017. Patients with a FC measurement ≥250 μg/g at diagnosis who also had at least 1 follow-up FC measurement within the first 12 months of diagnosis and >12 months of follow up were included. The last FC measurement within 12 months of diagnosis was used to determine normalization (cut-off <250 μg/g). The primary endpoint was time to first disease progression (composite of progression in Montreal disease behavior B1 to B2/3, B2 to B3, or new perianal disease; CD-related surgery; or CD-related hospitalization). Cox proportional hazards regression analysis was used to determine independent factors associated with time to first disease progression. RESULTS: A total of 375 patients out of 1389 incident cases were included, with a median follow up of 5.3 years (interquartile range, 3.1-7.4 years). Normalization of FC within 12 months of diagnosis was confirmed in 43.5% of patients. Patients with normalized levels of FC had a significantly lower risk of composite disease progression (hazard ratio [HR], 0.36; 95% CI, 0.24-0.53; P < .001). They also had a lower risk of reaching any of the separate progression endpoints (progression in Montreal behavior or new perianal disease HR, 0.22; 95% CI, 0.11-0.45; P < .001; hospitalization HR, 0.33; 95% CI, 0.21-0.53; P <.001; surgery HR, 0.39; 95% CI, 0.19-0.78; P = .008) CONCLUSIONS: Normalization of FC within 12 months of diagnosis is associated with a reduced risk of progression of CD.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Plevris N, Fulforth J, Lyons M, et al. Normalization of Fecal Calprotectin Within 12 Months of Diagnosis Is Associated With Reduced Risk of Disease Progression in Patients With Crohn's Disease. Clin Gastroenterol Hepatol. 2020. PMID: 32798706. doi:10.1016/j.cgh.2020.08.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。